-
Mashup Score: 3Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States - 1 month(s) ago
Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market. This launch adds to Teva’s continued commitment to its complex generic medicine portfolio. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza ®1 (liraglutide injection 1.8mg), in the United States. “By launching an authorized generic for Victoza ® (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva. “In addition to strengthening
Source: ir.tevapharm.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO ® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion. AJOVY ® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023. UZEDY ® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million. Early and late-stage innovative pipeline continues to progress, with duvakitug (Anti-TL1A) top-line results expected in Q4 2024, and TEV-‘749 (olanzapine LAI) achieving phase III target injections without PDSS. Generics business grows across all regions – increased by 30% in the U.S., 8% in Europe and 13% in International Markets, in local currency terms compared
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2024 business results. https://t.co/P8rEXLxooh Forward-looking statements are subject to the cautionary note included in our Q3 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/kdh7MEPSBd
-
-
Mashup Score: 4
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO ® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion. AJOVY ® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023. UZEDY ® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million. Early and late-stage innovative pipeline continues to progress, with duvakitug (Anti-TL1A) top-line results expected in Q4 2024, and TEV-‘749 (olanzapine LAI) achieving phase III target injections without PDSS. Generics business grows across all regions – increased by 30% in the U.S., 8% in Europe and 13% in International Markets, in local currency terms compared
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2024 business results. https://t.co/P8rEXLxooh Forward-looking statements are subject to the cautionary note included in our Q3 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/kdh7MEPSBd
-
-
Mashup Score: 4
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara ® (ustekinumab) in the U.S. at launch, which is expected
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: The U.S. FDA approves an expanded label for one of our partnered #biosimilar products, extending to use in treatment of adults with Crohn’s disease and ulcerative colitis. Read more here: https://t.co/N60EM1e59S https://t.co/jvBgpFXDVQ
-
-
Mashup Score: 4Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA - 3 month(s) ago
Prolia ® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such as oncology, immunology and respiratory medicine Anticipated decision by both agencies is expected in 2H 2025 TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia ® (denosumab). 1 Both applications, a Biologics License Application (BLA) in the U.S., seeking interchangeability, and a Marketing Authorization Application (MAA) in the
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: The U.S. Food and Drug Administration has accepted and the European Medicines Agency has validated applications for one of our biosimilar candidates. Read more here: https://t.co/Hjq82Ytm6Y https://t.co/6Und85woRS
-
-
Mashup Score: 7Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance - 5 month(s) ago
For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compared to Q2 2023. Generics business grows across all regions – increased in local currency terms by 16% in the U.S., 8% in Europe and 22% in International Markets, compared to Q2 2023. AUSTEDO – continued growth, U.S. revenue of $407 million in Q2 2024, an increase of 32% compared to Q2 2023; raising 2024 revenue outlook to ~$1.6 billion. AJOVY ® – global revenues of $115 million in Q2 2024, an increase of 12% in local currency terms compared to Q2 2023. Announced acceleration of development timeline for duvakitug (Anti-TL1A) – top-line results now expected in Q4 2024, with full data expected next year. Announced positive Phase 3 efficacy results for olanzapine LAI (TEV’ 749); so far completed ~95% of target injections with no PDSS observed. SIMLANDI ® (adalimumab-ryvk) injection launched in May
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q2 2024 business results. https://t.co/SbL6uXSWjo Forward-looking statements are subject to the cautionary note included in our Q2 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/idrJMVfJEA
-
-
Mashup Score: 9Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease - 5 month(s) ago
Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment Topline results for both UC and CD now anticipated in Q4 2024 Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug (anti-TL1A) for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD) patients Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Sanofi today announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for moderate-to-severe IBD. Patient enrollment in the RELIEVE UCCD (ulcerative colitis and Crohn’s disease) Phase 2b trial has completed early due to significant acceleration in patient recruitment. As a result, Teva and Sanofi now anticipate having topline results for both UC and CD in Q4 2024, and detailed results will be presented in a
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Partnering for better health with @Sanofi to bring much-needed innovations in treatment options for patients with #IBD, today we are announcing an update and accelerated timeline for our anti-tl1a Phase 2b clinical trial. Read more here: https://t.co/zuJHBoBwzP https://t.co/F9c4AeF3be
-
-
Mashup Score: 3Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 - 7 month(s) ago
Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia (TD) including social, psychological, physical and recreational aspects of daily living Data highlight for the first time that TD has a multidimensional impact on patients including those with mild TD severity IMPACT-TD Registry is the largest-ever study of its kind evaluating the holistic effects of TD over three years along with real-world treatment patterns and outcomes with once-daily AUSTEDO® XR (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO® (deutetrabenazine) tablets Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: At #PsychCongressElevate2024, we presented results from the IMPACT-TD study. The registry and study evaluate the holistic effects of tardive dyskinesia along with real-world treatment outcomes. Learn more here: https://t.co/qgnDreuSmv https://t.co/yCPV6tT5Zu
-
-
Mashup Score: 0
The study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘749 dose groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total score, a widely used assessment tool for schizophrenia symptom severity TEV-‘749 was well tolerated, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date: additional safety data is being collected as part of the long-term follow-up SOLARIS study TEV-‘749 is being developed by Teva as a once-monthly subcutaneous long-acting injection of olanzapine with the use of SteadyTeq™ technology, a copolymer technology proprietary to Medincell Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: New Phase 3 efficacy data from our SOLARIS trial show the potential of a long-acting treatment for #schizophrenia. Learn more here: https://t.co/OL1Moz2hKV https://t.co/8Uu0nedFm9
-
-
Mashup Score: 11Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate - 9 month(s) ago
Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step in mAbxience’s global expansion strategy and advances a key element of Teva’s Pivot to Growth strategy to expand its biosimilar pipeline through business development Teva-mAbxience partnership reflects the companies’ shared commitment to expand access to critical healthcare solutions to more patients who need them Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective alternatives to existing oncology therapies, thereby addressing a critical need in
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Teva announced a strategic global licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Learn more here: https://t.co/rqNbg3P0CA #Tevapharm #Oncology #PivotToGrowth https://t.co/3IIDVw9rfb
-
RT @brendonneuen: Generic GLP-1RA liraglutide launched in the United States Details from June 2024 press release: https://t.co/QUtqDgNaMy.